Download - Cancer Exosomes
-
8/4/2019 Cancer Exosomes
1/34
A Novel Therapeutic Strategyto AddressCancer
September 2011
-
8/4/2019 Cancer Exosomes
2/34
Canceris the leading cause of deathworldwide and accounted for 7.6 million
deaths in 2008 alone
-
8/4/2019 Cancer Exosomes
3/34
There were 12.7 million new cases ofCancer in 2008
-
8/4/2019 Cancer Exosomes
4/34
Cancerdeaths in the United Statesare expected to exceed 570,000 in 2011
-
8/4/2019 Cancer Exosomes
5/34
-
8/4/2019 Cancer Exosomes
6/34
In 2011, new cases of Cancer areexpected to exceed 1,500,000 in the U.S.
-
8/4/2019 Cancer Exosomes
7/34
-
8/4/2019 Cancer Exosomes
8/34
Innovative strategies are needed
to address Cancer progressionmechanisms that are beyond thereach of current drug therapies
-
8/4/2019 Cancer Exosomes
9/34
A therapeutic strategy that could inhibit the
proliferation of immunosuppressive exosomesreleased by solid tumors, lymphomas andleukemias would fill a significant unmetmedical need in cancer care
-
8/4/2019 Cancer Exosomes
10/34
What are Exosomes?
Cancer cells, both in vivoand in vitro, have beendemonstrated to releasemembranous structures,defined as exosomes
-
8/4/2019 Cancer Exosomes
11/34
Researchers have recently unveiled severalroles that exosomes play in acceleratingcancer progression
-
8/4/2019 Cancer Exosomes
12/34
The resulting research publicationsare reporting that................
-
8/4/2019 Cancer Exosomes
13/34
Exosomes cause apoptosis or programmedcell death of immune cells
-
8/4/2019 Cancer Exosomes
14/34
Exosomes disrupt signaling ofanti-cancer T cells
-
8/4/2019 Cancer Exosomes
15/34
Exosomes contribute to tumor angiogenesis
-
8/4/2019 Cancer Exosomes
16/34
Exosomes enhance the spread of tumor metastasis
-
8/4/2019 Cancer Exosomes
17/34
The quantity of exosomes in circulation is indirect correlation with cancer progression
-
8/4/2019 Cancer Exosomes
18/34
What if exosomes could beeliminated from circulation?
-
8/4/2019 Cancer Exosomes
19/34
The first therapeutic candidate to eliminatecancer exosomes from circulation
The Aethlon Hemopurifier
-
8/4/2019 Cancer Exosomes
20/34
The Aethlon Hemopurifier
Provides a therapeutic filtration
mechanism to remove cancer
exosomes from the circulatory
system
Allows selective exosome capture
via unique high-mannose
signatures resident on exosomesurfaces
-
8/4/2019 Cancer Exosomes
21/34
Providing access to the entire
circulatory system
Exosomes can be accessed
from entire circulatory system,
which can pass through the
Hemopurifier in as little as
15 minutes
-
8/4/2019 Cancer Exosomes
22/34
Hemopurifier therapy has the advantage of being
delivered through the global infrastructure of dialysis
machines that are already located in hospitals in clinics
-
8/4/2019 Cancer Exosomes
23/34
Our goal is to improve patient responsivenessto traditional chemotherapies and emergingclasses of immune based therapies
-
8/4/2019 Cancer Exosomes
24/34
To improve patient responsiveness withoutadditional drug toxicity or interaction risks
-
8/4/2019 Cancer Exosomes
25/34
In vitro binding of exosomes underlying thefollowing cancers has been demonstrated
Breast
Ovarian
Colorectal
Lymphoma
Melanoma
-
8/4/2019 Cancer Exosomes
26/34
Human Hemopurifier treatmentexperience already exists
-
8/4/2019 Cancer Exosomes
27/34
The Hemopurifier has previously demonstrated
the ability to reduce viral load in HIV andhepatitis C (HCV) infected individuals without theadministration of antiviral drugs
-
8/4/2019 Cancer Exosomes
28/34
A clinical study to evaluate the ability of the
Hemopurifier to improve HCV drug therapybenefit is currently being conducted
-
8/4/2019 Cancer Exosomes
29/34
The clinical application of theHemopurifier in Cancer?
-
8/4/2019 Cancer Exosomes
30/34
We are currently col laborating withcandidate investigators to develop a clinicalprotocol to demonstrate the ability of ourHemopurifier to eliminate circulatingcancer exosomes
-
8/4/2019 Cancer Exosomes
31/34
We invite you to follow our efforts
to improve cancer care
AethlonMedical.com
-
8/4/2019 Cancer Exosomes
32/34
Our mission is to create innovative devices thataddress unmet medical needs in cancer, infectious
disease, and other life-threatening conditions
Thank You
-
8/4/2019 Cancer Exosomes
33/34
Contact
Jim Joyce
Chairman, CEO
8910 University Center Lane
San Diego, California [email protected]
-
8/4/2019 Cancer Exosomes
34/34
This presentation contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, and Aethlon Medical intends that such forward-looking statements be
subject to the safe harbor created thereby. These statements are based on managements current
expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could
cause actual results to differ materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking statements, including the companys
ability to successfully obtain FDA and other regulatory approvals for the sale of its products, the
capability of the Hemopurifier to reduce viral loads and other disease conditions or to identify or treatdisease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the
impact that potential ability may have on disease conditions, and the companys ability to raise capital
when needed.
Some information in this presentation, or on which this presentation is based, has been obtained from
sources that Aethlon Medical, Inc., believes to be reliable and accurate. However, it has not been
independently verified and no representation or warranty, express or implied, is made as to the accuracy
or completeness of any information obtained from third parties.
Such risks and uncertainties, including those discussed above, are more fully described in the Securities
and Exchange Commission (SEC) reports filed by Aethlon Medical, Inc., including its most recent annual
report on Form 10-K. This presentation speaks only as of its date, and the company disclaims any duty
to update the information herein. Further information is available by contacting the company or at the
companys website at www.aethlonmedical.com.